Page last updated: 2024-10-23

atenolol and Albuminuria

atenolol has been researched along with Albuminuria in 28 studies

Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

ExcerptRelevanceReference
"The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension."9.13Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008)
"Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events."9.12Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006)
"To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria."9.11Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004)
"8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."9.11Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005)
"Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria."7.68Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991)
"With ramipril treatment urinary albumin creatinine ratio (14."6.68Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996)
" atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)."5.20Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015)
"The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol."5.13Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008)
"The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension."5.13Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008)
"Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events."5.12Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006)
"To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria."5.11Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004)
"8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study."5.11Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005)
"Given a similar level of arterial pressure control, both lisinopril and diltiazem slow progression of diabetic renal disease and reduce albuminuria to a greater extent than does the combination of a loop diuretic and beta-adrenoreceptor antagonist."5.07Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. ( Bakris, GL; Sadler, R; Slataper, R; Vicknair, N, 1993)
"We prospectively measured UAE prior to and 4 and 8 weeks after treatment with enalapril, nitrendipine, atenolol, or a diuretic in 48 patients with essential hypertension and microalbuminuria."5.07Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. ( Baldari, G; Bianchi, S; Bigazzi, R; Campese, VM, 1992)
"In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen."3.76Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010)
"In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen."3.73Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006)
"Fifty patients with stable slight and moderate uncomplicated essential hypertension, treated by ramipril, atenolol, or isradipine, were examined."3.70[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]. ( Betekhtina, VA; Rakov, SS, 2000)
"Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria."3.68Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991)
"1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8."2.69Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998)
"With ramipril treatment urinary albumin creatinine ratio (14."2.68Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996)
"The progression of diabetic nephropathy can be positively influenced by maintaining a low blood pressure level."2.67Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. ( Berden, JH; de Nobel, E; Elving, LD; van Lier, HJ; Wetzels, JF, 1994)
"Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function."2.67Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19902 (7.14)18.7374
1990's12 (42.86)18.2507
2000's11 (39.29)29.6817
2010's3 (10.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vishram, JK1
Dahlöf, B8
Devereux, RB7
Ibsen, H7
Kjeldsen, SE6
Lindholm, LH6
Mancia, G1
Okin, PM4
Rothwell, PM1
Wachtell, K8
Olsen, MH8
Søraas, CL1
Tønnessen, T1
Matsui, Y1
Eguchi, K1
Shibasaki, S1
Ishikawa, J1
Hoshide, S1
Shimada, K1
Kario, K1
Borch-Johnsen, K4
Mogensen, CE3
de Faire, U2
Fyhrquist, F2
Julius, S3
Lederballe-Pedersen, O2
Nieminen, MS4
Omvik, P2
Oparil, S2
Wan, Y3
Bella, JN1
Palmieri, V1
Gerdts, E1
Smith, G1
Snapinn, SM1
Lyle, PA1
Oikarinen, L2
Kamgar, M1
Nobakhthaghighi, N1
Shamshirsaz, AA1
Estacio, RO1
McFann, KK1
Schrier, RW1
Viitasalo, M1
Toivonen, L1
Barrios, V1
Escobar, C1
Tomás, JP1
Calderon, A1
Echarri, R1
Elving, LD1
Wetzels, JF1
van Lier, HJ1
de Nobel, E1
Berden, JH1
Nielsen, FS2
Rossing, P2
Gall, MA2
Skøtt, P2
Smidt, UM2
Parving, HH2
Slataper, R1
Vicknair, N1
Sadler, R1
Bakris, GL1
Rangemark, C1
Lind, H1
Lindholm, L1
Hedner, T2
Samuelsson, O2
Schnack, C1
Hoffmann, W1
Hopmeier, P1
Schernthaner, G1
Kribben, A1
Anlauf, M1
Distler, A1
Gärtner, H1
Holzgreve, H1
Michaelis, J1
Röcker, L1
Schäfers, R1
Philipp, U1
Wellek, S1
Philipp, T1
Rakov, SS1
Betekhtina, VA1
Redon, J1
Rovira, E1
Miralles, A1
Julve, R1
Pascual, JM1
Stornello, M1
Valvo, EV1
Scapellato, L1
Ljungman, S1
Herlitz, H1
Widgren, B1
Pennert, K1
Bianchi, S1
Bigazzi, R1
Baldari, G1
Campese, VM1
Tindall, H2
Urquhart, S1
Stickland, M1
Davies, JA2
Hopper, AH1
Christensen, CK1
Krusell, LR1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]Phase 3496 participants (Actual)Interventional1995-06-30Completed
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966]Phase 2174 participants (Anticipated)Interventional2022-12-30Not yet recruiting
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]150 participants (Anticipated)Interventional2016-11-30Active, not recruiting
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601]Phase 3170 participants Interventional2005-02-28Completed
The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816]197 participants (Actual)Interventional2017-05-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

20 trials available for atenolol and Albuminuria

ArticleYear
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
    Journal of hypertension, 2015, Volume: 33, Issue:12

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu

2015
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
    Journal of hypertension, 2004, Volume: 22, Issue:9

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics;

2004
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr

2005
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    American journal of hypertension, 2005, Volume: 18, Issue:11

    Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double-

2005
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
    Diabetes care, 2006, Volume: 29, Issue:3

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr

2006
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
    American journal of hypertension, 2008, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin

2008
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
    Clinical therapeutics, 2008, Volume: 30, Issue:1

    Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery,

2008
Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.
    Diabetologia, 1994, Volume: 37, Issue:6

    Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephrop

1994
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
    Diabetes, 1994, Volume: 43, Issue:9

    Topics: Albuminuria; Apolipoproteins; Apoprotein(a); Atenolol; Blood Pressure; Circadian Rhythm; Diabetes Me

1994
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
    Archives of internal medicine, 1993, Apr-26, Volume: 153, Issue:8

    Topics: Albuminuria; Antihypertensive Agents; Atenolol; Diabetic Nephropathies; Diltiazem; Dipeptides; Furos

1993
Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.
    European journal of clinical pharmacology, 1996, Volume: 49, Issue:4

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cross-

1996
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
    Diabetologia, 1996, Volume: 39, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol;

1996
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
    Diabetes, 1997, Volume: 46, Issue:7

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Ateno

1997
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
    Kidney international. Supplement, 1997, Volume: 61

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Ant

1997
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
    BMJ (Clinical research ed.), 1998, Sep-12, Volume: 317, Issue:7160

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive

1998
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.
    Hypertension (Dallas, Tex. : 1979), 2002, Mar-01, Volume: 39, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihyper

2002
Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
    Clinical science (London, England : 1979), 1992, Volume: 82, Issue:1

    Topics: Adult; Aged; Albuminuria; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathie

1992
A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:5

    Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blo

1992
Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs.
    The American journal of medicine, 1992, Volume: 93, Issue:5

    Topics: Adult; Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Atenolol; Creatinine; Diure

1992
Acute and long-term effect of antihypertensive treatment on exercise induced microalbuminuria in essential hypertension.
    Journal of clinical hypertension, 1987, Volume: 3, Issue:4

    Topics: Adult; Albuminuria; Atenolol; beta 2-Microglobulin; Blood Pressure; Clinical Trials as Topic; Double

1987

Other Studies

8 other studies available for atenolol and Albuminuria

ArticleYear
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Blood pressure, 2010, Volume: 19, Issue:3

    Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol,

2010
Impact of arterial stiffness reduction on urinary albumin excretion during antihypertensive treatment: the Japan morning Surge-1 study.
    Journal of hypertension, 2010, Volume: 28, Issue:8

    Topics: Aged; Albuminuria; Ankle Brachial Index; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Bra

2010
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Journal of hypertension, 2006, Volume: 24, Issue:4

    Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr

2006
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
    Kidney international, 2006, Volume: 69, Issue:10

    Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat

2006
[Kidney protection leads to heart protection, too].
    MMW Fortschritte der Medizin, 2006, Aug-17, Volume: 148, Issue:33-34

    Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive

2006
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
    Klinicheskaia laboratornaia diagnostika, 2000, Issue:7

    Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement

2000
Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients.
    Current medical research and opinion, 1991, Volume: 12, Issue:8

    Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephro

1991
The course of incipient diabetic nephropathy.
    Diabetic medicine : a journal of the British Diabetic Association, 1986, Volume: 3, Issue:3

    Topics: Adult; Albuminuria; Atenolol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Middle Aged

1986